Vitamin D and pancreatic cancer

Cancer Letters

Volumn 368, Issue 1, 2015, Pages 1-6

  Barreto, Savio G ^a   Neale, Rachel E ^b  

^a Medanta Institute of Digestive and Hepatobiliary Sciences   (India)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Chemotherapy; Epidemiology; Outcome; Surgery

Indexed keywords

20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; 22 OXACALCITRIOL; ALITRETINOIN; CALCIPOTRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CELL SURFACE RECEPTOR; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOCETAXEL; DOXERCALCIFEROL; GEMCITABINE; PARICALCITOL; RETINOIC ACID; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOL DERIVATIVE; SEOCALCITOL; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; CALCITRIOL RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER TISSUE; DRUG RECEPTOR BINDING; FATIGUE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; MONOTHERAPY; NONHUMAN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DIET SUPPLEMENTATION; METABOLISM; PANCREATIC NEOPLASMS; RISK FACTOR; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; DIETARY SUPPLEMENTS; HUMANS; PANCREATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84940733469     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.06.030     Document Type: Review

References (61)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin 2015, 65(2):87-100.
2. Shrikhande S., Barreto S. Surgery for pancreatic carcinoma: state of the art. Indian J. Surg 2012, 74:79-86.
3. Shukla P.J., Barreto G., Shrikhande S.V. The evolution of pancreatoduodenectomy. Hepatogastroenterology 2011, 58:1409-1412.
4. Shrikhande S.V., Barreto S.G. Extended pancreatic resections and lymphadenectomy: an appraisal of the current evidence. World J. Gastrointest. Surg 2010, 2:39-46.
5. Shrikhande S.V., Barreto S.G., Somashekar B.A., Suradkar K., Shetty G.S., Talole S., et al. Evolution of pancreatoduodenectomy in a tertiary cancer center in India: improved results from service reconfiguration. Pancreatology 2013, 13:63-71.
6. Paulson A.S., Tran Cao H.S., Tempero M.A., Lowy A.M. Therapeutic advances in pancreatic cancer. Gastroenterology 2013, 144:1316-1326.
7. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
8. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014, 74:2913-2921.
9. Hartwig W., Werner J., Jager D., Debus J., Buchler M.W. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013, 14:e476-e485.
10. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med 2013, 369:1691-1703.
11. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med 2011, 364:1817-1825.
12. Nienhuijs S.W., van den Akker S.A., de Vries E., de Hingh I.H., Visser O., Lemmens V.E. Nationwide improvement of only short-term survival after resection for pancreatic cancer in The Netherlands. Pancreas 2012, 41:1063-1066.
13. Vuolo L., Di Somma C., Faggiano A., Colao A. Vitamin D and cancer. Front. Endocrinol. (Lausanne) 2012, 3:58.
14. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7:684-700.
15. Forouhi N.G., Luan J., Cooper A., Boucher B.J., Wareham N.J. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008, 57:2619-2625.
16. Steddon S.J., Schroeder N.J., Cunningham J. Vitamin D analogues: how do they differ and what is their clinical role?. Nephrol. Dial. Transplant 2001, 16:1965-1967.
17. Lehmann B. The vitamin D3 pathway in human skin and its role for regulation of biological processes. Photochem. Photobiol 2005, 81:1246-1251.
18. Sprague S.M., Llach F., Amdahl M., Taccetta C., Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003, 63:1483-1490.
19. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
20. Mohr S.B., Garland C.F., Gorham E.D., Grant W.B., Garland F.C. Ultraviolet B irradiance and vitamin D status are inversely associated with incidence rates of pancreatic cancer worldwide. Pancreas 2010, 39:669-674.
21. Neale R.E., Youlden D.R., Krnjacki L., Kimlin M.G., van der Pols J.C. Latitude variation in pancreatic cancer mortality in Australia. Pancreas 2009, 38:387-390.
22. Tran B., Whiteman D.C., Webb P.M., Fritschi L., Fawcett J., Risch H.A., et al. Association between ultraviolet radiation, skin sun sensitivity and risk of pancreatic cancer. Cancer Epidemiol 2013, 37:886-892.
23. Genkinger J.M., Wang M., Li R., Albanes D., Anderson K.E., Bernstein L., et al. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Ann. Oncol 2014, 25:1106-1115.
24. Waterhouse M., Risch H.A., Bosetti C., Anderson K.E., Petersen G.M., Bamlet W.R., et al. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Ann. Oncol 2015, 6(8):1776-1783.
25. Stolzenberg-Solomon R.Z., Jacobs E.J., Arslan A.A., Qi D., Patel A.V., Helzlsouer K.J., et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol 2010, 172:81-93.
26. Wolpin B.M., Ng K., Bao Y., Kraft P., Stampfer M.J., Michaud D.S., et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev 2012, 21:82-91.
27. Anderson L.N., Cotterchio M., Knight J.A., Borgida A., Gallinger S., Cleary S.P. Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada. PLoS ONE 2013, 8:e66768.
28. Li L., Wu B., Yang L., Yin G., Wei W., Sui S., et al. Association of vitamin D receptor gene polymorphisms with pancreatic cancer: a pilot study in a North China population. Oncol. Lett 2013, 5:1731-1735.
29. Arem H., Yu K., Xiong X., Moy K., Freedman N.D., Mayne S.T., et al. Vitamin d metabolic pathway genes and pancreatic cancer risk. PLoS ONE 2015, 10:e0117574.
30. Wang K., Dong M., Sheng W., Liu Q., Yu D., Dong Q., et al. Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer. Histopathology 2015, 10.1111/his.12663.
31. Van Loon K., Owzar K., Jiang C., Kindler H.L., Mulcahy M.F., Niedzwiecki D., et al. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J. Natl Cancer Inst 2014, 106. 10.1093/jnci/dju185.
32. Cho M., Peddi P.F., Ding K., Chen L., Thomas D., Wang J., et al. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J. Transl. Med 2013, 11:206.
33. Zugmaier G., Jager R., Grage B., Gottardis M.M., Havemann K., Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br. J. Cancer 1996, 73:1341-1346.
34. Kawa S., Yoshizawa K., Tokoo M., Imai H., Oguchi H., Kiyosawa K., et al. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 1996, 110:1605-1613.
35. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., et al. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer 1997, 76:884-889.
36. Colston K.W., James S.Y., Ofori-Kuragu E.A., Binderup L., Grant A.G. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br. J. Cancer 1997, 76:1017-1020.
37. Koike N., Endo K., Kubodera N., Kumaki K., Ikeda K., Ogata E., et al. In vivo nuclear uptake of a vitamin D analog (OCT) in different tumor cell populations of FA-6 cancer xenograft in nude mice by receptor autoradiography. Anticancer Res 1999, 19:4955-4958.
38. Pettersson F., Colston K.W., Dalgleish A.G. Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br. J. Cancer 2000, 83:239-245.
39. Albrechtsson E., Jonsson T., Moller S., Hoglund M., Ohlsson B., Axelson J. Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number. Pancreatology 2003, 3:41-46.
40. Schwartz G.G., Eads D., Rao A., Cramer S.D., Willingham M.C., Chen T.C., et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 2004, 25:1015-1026.
41. Ohlsson B., Albrechtsson E., Axelson J. Vitamins A and D but not E and K decreased the cell number in human pancreatic cancer cell lines. Scand. J. Gastroenterol 2004, 39:882-885.
42. Kawa S., Yoshizawa K., Nikaido T., Kiyosawa K. Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J. Steroid Biochem. Mol. Biol 2005, 97:173-177.
43. Mouratidis P.X., Dalgleish A.G., Colston K.W. Investigation of the mechanisms by which EB1089 abrogates apoptosis induced by 9-cis retinoic acid in pancreatic cancer cells. Pancreas 2006, 32:93-100.
44. Schwartz G.G., Eads D., Naczki C., Northrup S., Chen T., Koumenis C. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther 2008, 7:430-436.
45. Persons K.S., Eddy V.J., Chadid S., Deoliveira R., Saha A.K., Ray R. Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells. Anticancer Res 2010, 30:1875-1880.
46. Yu W.D., Ma Y., Flynn G., Muindi J.R., Kong R.X., Trump D.L., et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 2010, 9:3022-3029.
47. Bruggemann L.W., Queiroz K.C., Zamani K., van Straaten A., Spek C.A., Bijlsma M.F. Assessing the efficacy of the hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer. Cancer Biol. Ther 2010, 10:79-88.
48. Takata T., Ishigaki Y., Shimasaki T., Tsuchida H., Motoo Y., Hayashi A., et al. Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Oncol. Rep 2012, 28:1968-1976.
49. Chiang K.C., Yeh C.N., Hsu J.T., Yeh T.S., Jan Y.Y., Wu C.T., et al. Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. Cell Cycle 2013, 12:1316-1325.
50. Kanemaru M., Maehara N., Chijiiwa K. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in human pancreatic cancer cells. Hepatogastroenterology 2013, 60:1199-1205.
51. Chiang K.C., Yeh C.N., Hsu J.T., Jan Y.Y., Chen L.W., Kuo S.F., et al. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells. Cancer Lett 2014, 354:235-244.
52. Hummel D., Aggarwal A., Borka K., Bajna E., Kallay E., Horvath H.C. The vitamin D system is deregulated in pancreatic diseases. J. Steroid Biochem. Mol. Biol 2014, 144(Pt B):402-409.
53. Sherman M.H., Yu R.T., Engle D.D., Ding N., Atkins A.R., Tiriac H., et al. Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014, 159:80-93.
54. Li Z., Guo J., Xie K., Zheng S. Vitamin D receptor signaling and pancreatic cancer Cell EMT. Curr. Pharm. Des 2015, 21(10):1262-1267.
55. Bhattacharjee V., Zhou Y., Yen T. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 2014, 13:3839-3856.
56. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
57. Evans T.R., Colston K.W., Lofts F.J., Cunningham D., Anthoney D.A., Gogas H., et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 2002, 86:680-685.
58. Barreto S.G., Ramadwar M.R., Shukla P.J., Shrikhande S.V. Vitamin D3 in operable periampullary and pancreatic cancer: perioperative outcomes in a pilot study assessing safety. Pancreas 2008, 36:315-317.
59. Blanke C.D., Beer T.M., Todd K., Mori M., Stone M., Lopez C. Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest. New Drugs 2009, 27:374-378.
60. Vogel I., Kruger U., Marxsen J., Soeth E. Disseminated tumour cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin. Cancer Res 1999, 5:593-599.
61. Hsu J.W., Yasmin-Karim S., King M.R., Wojciechowski J.C., Mickelsen D., Blair M.L., et al. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha,25-dihydroxyvitamin D3. Am. J. Pathol 2011, 178:872-880.